FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization
Verquvo is the first soluble guanylate cyclase stimulator drug cleared by FDA to treat heart failure
January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics.
The drug is supposed to reduce the risk of cardiovascular death and heart failure hospitalization in indicated patients with symptomatic chronic heart failure and ejection fraction less than 45%. Vericiguat is a soluble guanylate cyclase (sGC) stimulator, and is the first drug in this class ro be cleared by the FDA for heart failure.